Study Evaluating Diltiazem in Combination With Standard Treatment in the Management of Patients Hospitalized With COVID-19 Pneumonia

Inclusion Criteria: * Male or female aged 18 or over * SARS-CoV-2 infection proven by RT-PCR on a nasopharyngeal sample within 72 hours prior to inclusion in the study * Onset of symptoms of viral infection ≤ 7 days * Hospitalization required due to hypoxemia (air saturation \< 94% at rest) * Presence of radiological pneumopathy (chest X-ray or non-enhanced thoracic CT) * Patient affiliated to a social security scheme. * Patient capable of giving free, informed and written consent. * Patient with a history of SARS-CoV-2 infection may participate in the study, but this infection must not have occurred within the 3 months prior to his current hospitalization. * Patient who has been vaccinated against SARS-CoV-2 can participate in the study (regardless of the number of doses) * Patient not eligible for specific anti-COVID treatment authorized in France (MA or early access) and not part of the standard of care at the time of the study * Female patient of childbearing age using effective contraception during study participation, the same applies to partners of childbearing age of male patients. Male patients must use condoms. Exclusion Criteria: * Need for hospitalization in intensive care unit at inclusion * Patient with cognitive impairment, at the discretion of the investigator * Pregnant woman (positive urine pregnancy test on inclusion) or breastfeeding * Participation in another interventional study or being in the exclusion period from a previous study * Patient on diltiazem therapy * Contraindication to diltiazem * Hypersensitivity to diltiazem or to any of the excipients * Unaided sinus dysfunction * Unaided 2nd and 3rd degree atrioventricular blocks * Left ventricular failure with pulmonary stasis (cardiogenic edema) * Severe bradycardia (≤ 40 beats per minute) * In combination with: dantrolene infusion, pimozide, dihydroergotamine, ergotamine, nifedipine, ivabradine, beta blockers, antiarrhythmics, esmolol, fingolimod. * Patient with renal, hepatic or cardiac insufficiency (at the discretion of the investigator) * Hypersensitivity to mannitol * Use of anti-COVID medications other than those offered in routine testing and care. * Presence of hemodynamic instability, systolic blood pressure \< 100 mmHg, presence of multi-visceral failure * Prior respiratory pathology requiring oxygen therapy at the long-term and/or non-invasive ventilation * Immunocompromised patients (organ transplant, allograft, under chemotherapy, under Rituximab or a history of Rituximab), for any other situation seek the advice of the coordinating investigator * Patient under guardianship, curatorship or safeguard of justice